Linc

Linc Diluted EPS

The Diluted Earnings per Share of Linc (LINC.ST) as of Oct 21, 2026 is -6.90 SEK. In the previous year, Diluted Earnings per Share was 22.48 SEK — a change of -130.70% (lower).

Diluted EPS

-6.90SEK

YoY

-130.70%

Last updated:

Diluted Earnings per Share of Linc is 2025 -6.90 SEK. Diluted Earnings per Share of Linc was 2024 22.48 SEK. It decreases by -130.70% lower compared to the previous year.

The Linc Diluted EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Diluted EPS
Date
Diluted EPS
Jan 1, 2018
5.46 SEK
Jan 1, 2019
10.30 SEK
Jan 1, 2020
13.56 SEK
Jan 1, 2021
-0.60 SEK
Jan 1, 2022
-12.49 SEK
Jan 1, 2023
10.70 SEK
Jan 1, 2024
22.48 SEK
Jan 1, 2025
-6.90 SEK
The Linc Diluted EPS history
YEARDiluted EPSYoY
-6.90SEK-130.70%
22.48SEK+110.12%
10.70SEK-185.64%
-12.49SEK+1,995.66%
-0.60SEK-104.39%
13.56SEK+31.74%
10.30SEK+88.71%
5.46SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Linc Stock analysis

What does Linc do? Linc AB generates revenue through long-term share ownership in Nordic life science companies, focusing on pharmaceutical and medical technology sectors. The company invests in both private and public firms, including early-stage drug development and operational medical technology companies. Linc Invest actively supports portfolio companies by collaborating with management, founders, and boards to unlock growth potential and drive expansion. Its industrial network enables strategic participation in nomination committees and development planning. The firm targets Nordic life science product-oriented companies, prioritizing pharmaceuticals and medical technology. Investments span research and operational phases, with drug development typically occurring earlier than in medical technology. Linc AB maintains a hands-on approach as a long-term owner, leveraging its network to assist portfolio companies in achieving ambitious development goals. Linc AB's business model centers on active ownership and strategic partnerships within the Nordic life science ecosystem. It focuses on companies with strong product pipelines, particularly in pharmaceuticals, where investments often occur during initial development stages. The company's role as a supportive shareholder drives value creation through collaborative governance and targeted expansion strategies. Linc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Linc stock

Diluted Earnings per Share of Linc is -6.90 SEK in 2025.

Diluted Earnings per Share of Linc changed from 22.48 SEK to -6.90 SEK, representing a -130.70% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Diluted Earnings per Share Linc since 2006 – with annual values, charts, and detailed analysis.

Diluted EPS accounts for all potential shares from options, warrants, and convertible securities. It provides a more conservative per-share earnings measure.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Linc

All Key Metrics — Linc